Meeting
2020 Genitourinary Cancers Symposium
A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer (mCRPC).
Authors
Michael C. Burns
Northwestern University, Chicago, IL
Michael C. Burns , Vinay Sagar , Borko Jovanovic , Alicia K. Morgans , David James VanderWeele , David I. Quinn , Walter Michael Stadler , Sarki Abdulkadir , Maha H. A. Hussain
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research
Clinical Trial Registration Number
NCT04033432
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr TPS274)
Abstract #
TPS274
Poster Bd #
P18
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase 1 efficacy and pharmacodynamic results of exicorilant + enzalutamide in patients with metastatic castration-resistant prostate cancer.
First Author: Michael J. Morris
Poster
2021 Genitourinary Cancers Symposium
Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer (mCRPC).
First Author: Fadi Taza
Poster
2019 ASCO Annual Meeting
AR changes in circulating-tumor DNA (ctDNA) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with high-dose testosterone.
First Author: Marcus W. Moses
Poster
2019 Genitourinary Cancers Symposium
Genomic changes of AR in ctDNA prior to enzalutamide in men with mCRPC after abiraterone acetate.
First Author: Leta Ko